Home
HEALTH CARE
Allergy and hay fever
Antineoplastic and immunomodulating agents
Circulatory system
Colds and flu
Dermatology
Digestive system
Eyes
For diabetics
Homeopathy
Musculoskeletal system
Non-sex hormones
Nutrikosmetics
Pain
Preparations for the treatment of infections
Sex and contraception
The immune system
The nervous system
Urogenital tract
Vitamins and minerals
HEALTHY LIFESTYLE
For athletes
Healthy food
Slimming
HYGIENE
Disinfection
Ear hygiene
Hot and cold compresses
Intimate hygiene
Laundry products
Oral hygiene
Slices and sticks
Urinary incontinence
COSMETICS
Cosmetic articles
For eyelashes and eyebrows
For face
For hair
For hands and nails
For the body
Soap
Sunbathing
To the feet
To the mouth
FOR HIM
Cosmetics for men
Health
PREGNANCY AND MOTHERHOOD
Accessories
Cosmetics for pregnant women
Health in pregnancy
Supporting fertility
CHILD
Baby nutrition
Child health
Cosmetics for children
Hygiene items for children
Oral hygiene (for children)
Scrolling
HEALTH CARE
Nasonex nasal spray 50 mcg/dose, 18 g (140 doses) — Made in Belgium — Free Delivery
Nasonex nasal spray 50 mcg/dose, 18 g (140 doses) — Made in Belgium — Free Delivery
Brand:
Schering-Plough Labo N.V.
Product Code:
Nasonex
Availability:
In Stock
$27.65
Add to Cart
Description
Product d
escription
Spray nasal "Nasonex®" is used for the following indications:
treatment of seasonal or perennial allergic rhinitis in adults and children over 2 years of age (prophylactic treatment of moderate to severe allergic rhinitis is recommended to start 4 weeks before the expected start of the dusting season);
as an auxiliary therapeutic agent in the treatment of acute sinusitis with antibiotics in adults (including the elderly) and children over 12 years of age;
treatment of symptoms of acute sinusitis without signs of severe bacterial infection in adults and children over 12 years of age;
Treatment of nasal polyps and related symptoms, including nasal congestion and loss of smell, in patients over the age of 18.
Structure
One spray dose contains (active ingredient) mometasone furoate monohydrate (micronized) in an amount equivalent to 50 μg of mometasone furoate (anhydrous).
Excipients: dispersed cellulose (microcrystalline cellulose and sodium carboxymethyl cellulose); glycerol; citric acid, monohydrate; sodium citrate, dihydrate; polysorbate-80; benzalkonium chloride solution; purified water.
Contraindications
Hypersensitivity to the active substance or to any inactive component of the drug.
Mode of application
Before using a new vial of the drug, it should be calibrated. Calibration is carried out by approximately 10 pushes of the dosing device, while a stereotyped delivery of the drug is established, in which approximately 100 mg of a suspension containing 50 μg of mometasone (one dose) is emitted with each press. If the nasal spray is not used for 14 days or longer, a second “spray” with 2 pressings must be observed before subsequent use until a complete delivery is observed. Do not pierce the tip before use.
Shake the bottle vigorously before each use.
If the nozzle is clogged, you need to remove the plastic cap by gently pressing on the white ring, easily remove the nozzle and rinse it with warm running water, dry it and reinstall it. Do not try to clean the nozzle with a needle or other sharp object, as doing so will damage the dispenser.
Regular cleaning of the nozzle is very important.
Before each use, thoroughly cleanse the nose of mucus.
Treatment of seasonal or year-round allergic rhinitis: for adults (including the elderly) and children over 12 years of age, the recommended prophylactic and therapeutic dose of the drug is 2 injections (50 μg each) into each nostril 1 time per day (total daily dose - 200 μg). After reaching the therapeutic effect for maintenance therapy, it is advisable to reduce the dose to one injection into each nostril 1 time per day (total daily dose - 100 mcg). If the weakening of the symptoms of the disease cannot be achieved by using the drug in the recommended therapeutic dose, the daily dose can be increased to the maximum: 4 injections into each nostril 1 time per day (total daily dose - 400 mcg). After the symptoms of the disease have subsided, a dose reduction is recommended. The drug demonstrated a clinically significant onset of action within 12 hours after the first use in some patients with seasonal allergic rhinitis. However, the full benefit of the treatment cannot be obtained in the first 48 hours, so the patient must continue to use it regularly to achieve the full therapeutic effect. For children 2-11 years old, the recommended therapeutic dose is one injection (50 mcg) into each nostril once a day (total daily dose is 100 mcg).
Adjunctive treatment of acute sinusitis. For adults (including the elderly) and children over 12 years of age, the recommended therapeutic dose is 2 injections (50 mcg each) into each nostril 2 times a day (total daily dose - 400 mcg). If the weakening of the symptoms of the disease cannot be achieved by using the drug in the recommended therapeutic dose, the daily dose can be increased to 4 injections into each nostril 2 times a day (total daily dose - 800 mcg). After the symptoms of the disease have subsided, a dose reduction is recommended.
Acute rhinosinusitis. For adults and children over 12 years of age, the recommended therapeutic dose is 2 injections (50 mcg) into each nostril 2 times a day (total daily dose is 400 mcg).
Nasal polyps. For patients over 18 years of age (including the elderly), the recommended dose is 2 injections (50 mcg) into each nostril 2 times a day (total daily dose is 400 mcg). After achieving the clinical effect, it is recommended to reduce the dose to 2 injections into each nostril once a day (total daily dose - 200 mcg).
Application features
Pregnant
Corticosteroid preparations should not be used by pregnant or breastfeeding women unless absolutely necessary.
Children
When conducting placebo-controlled clinical trials in children who received Nasonex® at a daily dose of 100 μg for a year, no growth retardation was observed. The safety and efficacy of Nasonex® in the treatment of nasal polyps in children and adolescents under the age of 18, symptoms of rhinosinusitis - under the age of 12, seasonal or perennial allergic rhinitis - in children under 2 years of age have not been investigated ...
Overdose
It is unlikely that an overdose will require any therapy other than monitoring.
Inhalation or oral administration of excessive doses of corticosteroids can lead to inhibition of the function of the hypothalamic-pituitary-adrenal system.
Side effects
The most common adverse reaction, epistaxis, occurred with approximately the same frequency in the placebo group (2.6%) and the Nasonex® group (2.9% and 3.7%, respectively).
Storage conditions
Store at a temperature not exceeding 25 ° C, out of the reach of children. Do not freeze.
Shelf life is 3 years.
0 reviews
There are no reviews for this product.